No current positioning snapshot.
Current snapshotPublic companyResearch currentFresh
Nano-X Imaging Ltd.
Intervene · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Intervene exposure in Healthspan Infrastructure.
Nano-X Imaging is developing a digital X-ray source and imaging platform
Catalysts
Q3 2026 preliminary revenue ~$4.3-4.4M vs $3.4M year-ago: teleradiology ~$3.1M (flat YoY), imaging systems/OEM ~$0.3M, balance AI/software (6-K/EX-99.1 10-16-26). Nanox.AI signed an Italian distribution deal for its Bone Solution with Technologic s.r.l.; Nanox.ARC X named a TIME Best Invention of 2026. Final Q3 results date not yet announced.
Invalidation
needs primary source validation — pending deep-dive research. Placeholder: (1) thesis chain breaks on primary-source evidence, (2) named revenue/customer concentration risk, (3) margin compression or competitive displacement
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
needs primary source validation — no X/Reddit signal yet
Lower-confidence snapshotTarget price: $4.19
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Toll Road Tier
- Strong proxy
Timestamped research update
Deep research update
461 words · Updated 22 Oct 2026 · 6 sources
Research in development: this latest 461-word update is published for context while it is expanded toward Guide-level depth (1,000+ words).
Nano-X Imaging Ltd. (None, CIK 0001795251) — US-listed company materially exposed to Medical Imaging Systems.
Nano-X Imaging Ltd. is an Israeli medical-imaging technology company that is trying to change the cost structure of X-ray imaging by replacing a traditional hot-cathode X-ray tube with a semiconductor-based digital X-ray source. Its stated ambition, repeated across SEC filings, is to produce lower-cost imaging hardware and then monetize imaging through a “medical imaging as a service” model: hardware plus cloud software, teleradiology, AI analytics, and per-scan or subscription fees.
From its SEC filings and public disclosures, NNOX’s product and service stack includes:
- Nanox.ARC — a multi-source digital tomosynthesis imaging system.
- Nanox.SOURCE — the underlying digital X-ray source technology.
- Nanox.CLOUD — cloud-based imaging software and data platform.
- Nanox.MARKETPLACE — an online marketplace connecting imaging providers and radiologists.
- Nanox.AI — AI population-health and diagnostic-imaging algorithms, traceable in part to NNOX’s acquisition of Zebra Medical Vision.
- Teleradiology and imaging-center services, traceable in part to NNOX’s acquisition of USARAD.
Those product names appear in NNOX’s SEC filings. However, the precise current product portfolio and regulatory status should be checked directly against the most recent 20-F because NNOX has repeatedly revised its commercialization narrative.
NNOX’s monetization model has three layers:
- Hardware sale or placement. The company sells or places imaging systems. In some deployments, the company may use a pay-per-scan arrangement rather than a single large capital purchase.
- Cloud and software fees. Nanox.CLOUD and AI algorithms can be sold as subscriptions or per-study fees.
- Teleradiology / marketplace take-rate. Through USARAD and Nanox.MARKETPLACE, NNOX can collect fees for radiology reading services or facilitate transactions between imaging providers and radiologists.
From the business model and the company’s stated strategy, the customer classes are:
- Hospitals and health systems — need high-throughput imaging, integration with PACS/EMR, and service reliability.
- Outpatient imaging centers — price-sensitive, volume-driven, likely candidates for pay-per-scan economics.
- Urgent care and specialty clinics — need smaller footprint and lower capital cost.
- Rural and underserved markets — NNOX’s stated target includes geographies with limited imaging access.
- Teleradiology providers and radiology groups — users of Nanox.MARKETPLACE and cloud AI.
- Population-health and screening programs — potential buyers of Nanox.AI algorithms.
No specific customer names are cited here because none were identified directly from the available filing excerpts in this session. If NNOX has material customer relationships, they may appear in contracts, exhibits, or risk-factor disclosures, but no name is invented.
Nano-X Imaging is developing a digital X-ray source and imaging platform
- Nano-X Imaging is developing a digital X-ray source and imaging platform source
- Nano-X Imaging Ltd. — SEC EDGAR company filings source
Competitor filings and market structure suggest that a small entrant cannot easily displace incumbent systems on price alone. Hospitals typically require clinical validation, service infrastructure, interoperability, and FDA-cleared indications before switching.
| Parameter | Value | Source | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| Price per scan | \$20 | Explicit assumption | Not applicable | Assumed | No |
| Scans/day | 40 | Explicit assumption | Not applicable | Assumed | No |
| Operating days/year | 300 | Explicit assumption | Not applicable | Assumed | No |
| Gross contribution margin | 60% | Explicit assumption | Not applicable | Assumed | No |
| Capital cost per system | \$250,000 | Explicit assumption | Not applicable | Assumed | No |
| NNOX FY2023 revenue | needs primary source validation | NNOX Form 20-F FY2023, filed 2024-03-28, EDGAR index | Tier 1 | Measured if verified | Single-source until verified |
| NNOX FY2023 cost of revenue | needs primary source validation | NNOX Form 20-F FY2023, EDGAR index | Tier 1 | Measured if verified | Single-source until verified |
| NNOX gross margin | Derived from revenue and cost of revenue; needs primary source validation | NNOX Form 20-F FY2023, EDGAR index | Tier 1 | Derived | No |
| Competitor imaging scale | needs primary source validation | GE HealthCare Form 10-K, EDGAR index | Tier 1 | Measured if verified | No |
_Pending primary-source company deep-dive._
Traditional X-ray tubes generate electrons by thermionic emission: a filament is heated to high temperature, releasing electrons that are accelerated into a metal anode to produce X-rays. This works well but involves high heat, relatively large packaging, and limited tube life.
NNOX’s stated core innovation is a field-emission cold cathode built on silicon-MEMS technology. Instead of heating a filament, an electric field extracts electrons from nanostructured emitters. Those electrons strike an anode to generate X-rays. The company argues that this approach can reduce size, weight, cooling requirements, and cost while enabling a different system architecture.
There is no evidence from SEC filings that NNOX currently has strong pricing power. The company is a challenger attempting to enter a market with large, trusted incumbents. In that position, NNOX must either:
- price below incumbent capital equipment, or
- offer a variable-cost pay-per-scan model that reduces upfront budget risk.
Both strategies are volume-dependent and dilutive to near-term margin. Pricing power would only emerge after NNOX has installed a large base, demonstrated clinical equivalence, and built switching costs through workflow integration. That condition is not yet visible in the filings reviewed.
_Pending primary-source company deep-dive._
The NNOX long thesis would be materially wrong if any of the following are true:
- Regulatory failure: FDA denies or does not expand clearances for Nanox.ARC or Nanox.SOURCE, or a major regulator withdraws clearance.
- No volume uptake: NNOX cannot install systems and generate meaningful scan volumes; deployments remain pilot-level or unused.
- Unit economics fail: Actual price per scan, utilization, or contribution margin is far below the assumptions in the worked calculation. If scans/day settle at 10–15 instead of 40, the pay-per-scan model is unattractive.
- Service and uptime problems: Early deployments show high failure rates or inability to meet hospital service-level agreements.
- Incumbent response: Siemens Healthineers, GE HealthCare, Philips, Canon, or Fujifilm launch directly competitive low-cost digital sources or bundle pricing to neutralize NNOX’s cost advantage.
- Teleradiology/AI margin compression: The service segments that currently provide revenue face pricing pressure, reducing the cash flow available to fund hardware commercialization.
- Cash runway breaks: NNOX’s liquidity falls below the level required to reach regulatory and commercial milestones; the company must raise capital on heavily dilutive terms.
- No reimbursement pathway: Payers treat Nanox.ARC scans as non-covered or investigative, preventing pay-per-scan adoption.
Any one of these would undermine the investment thesis. Several would likely be visible in a future 20-F risk-factor update before they become fully obvious in reported revenue.
INTACT (exposure surfaced from technology map; no capital allocation)
Primary and supporting material
Sources
6 sources preserved from the latest qualified research update.